Sign In
Buy PGEN
$3.81
-0.0500 (-1.30%)
At Close: Jun 03, 2026
Precigen Announces Pricing of $30.0 Million Public Offering of Common Stock
09:30pm, Wednesday, 07'th Aug 2024
GERMANTOWN, Md. , Aug. 7, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN) today announced the pricing of an underwritten public offering of 35,294,118 shares of its common stock at a public offeri
Earnings Preview: Precigen, Inc. (PGEN) Q2 Earnings Expected to Decline
11:06am, Wednesday, 07'th Aug 2024
Precigen (PGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Precigen Announces Proposed $30 Million Public Offering of Common Stock
04:04pm, Tuesday, 06'th Aug 2024
GERMANTOWN, Md. , Aug. 6, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN) today announced it has commenced a $30.0 million underwritten public offering of its common stock.
Precigen Strategically Prioritizes Portfolio to Focus on First Potential Gene Therapy Launch
04:01pm, Tuesday, 06'th Aug 2024
– PRGN-2012 is on track for a rolling BLA submission under an accelerated approval pathway; patient enrollment initiated in the confirmatory clinical trial – GERMANTOWN, Md. , Aug. 6, 2024 /PRNews
Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch
08:01am, Tuesday, 23'rd Jul 2024
– Company strengthens focus on building and optimizing commercial readiness and pre-launch activities for PRGN-2012 in recurrent respiratory papillomatosis – GERMANTOWN, Md. , July 23, 2024 /P
– Phase 1/2 pivotal study met the primary safety and efficacy endpoints – – 51% (18 out of 35) of patients achieved Complete Response, requiring no surgeries after treatment with PRGN-20
GERMANTOWN, Md. , May 23, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of
Precigen, Inc. (PGEN) Reports Q1 Loss, Misses Revenue Estimates
06:20pm, Tuesday, 14'th May 2024
Precigen, Inc. (PGEN) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.10 per share a year ago.
Precigen Reports First Quarter 2024 Financial Results and Business Updates
04:05pm, Tuesday, 14'th May 2024
– Pivotal Phase 2 study data of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis to be presented at the 2024 ASCO Annual Meeting as a late-breaking oral presenta
GERMANTOWN, Md. , May 8, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of
GERMANTOWN, Md. , April 24, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives
Actym Therapeutics Appoints Thomas Smart as CEO
09:00am, Wednesday, 24'th Apr 2024
BERKELEY, Calif. , April 24, 2024 /PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer.
Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th
04:05pm, Thursday, 28'th Mar 2024
– Inaugural multi-stakeholder event on June 11th (6/11) will raise awareness and bring together individuals living with RRP, caregivers, clinicians, and government officials – – RRP is a
Precigen, Inc. (PGEN) Q4 2023 Earnings Call Transcript
08:49pm, Tuesday, 19'th Mar 2024
Precigen, Inc. (PGEN) Q4 2023 Earnings Call Transcript
Precigen Reports Full Year 2023 Financial Results and Business Updates
04:05pm, Tuesday, 19'th Mar 2024
– Significant progress made in the development of the PRGN-2012 AdenoVerse immunotherapy for the treatment of RRP; Precigen plans to submit a BLA under an accelerated approval pathway in the seco
